Why not just use alpha-MSH?

It drives pigmentation through melanocortin receptors, which is a confound for anti-inflammatory research. The fragment separates the two activities.

Does KPV work the same way as its parent?

Not necessarily. At a fifth of the mass it may access compartments alpha-MSH cannot, so the mechanisms may differ.

What limits KPV in practice?

Delivery. The published targeted-delivery work indicates the free tripeptide's arrival at intended tissue was the obstacle.

KPV

Fragment Logic: KPV Against Its Parent

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Alpha-MSH has two functionally separable activities — pigmentation and anti-inflammation. Isolating the C-terminal tripeptide keeps the second without the first, which is the entire rationale for KPV existing as a distinct research compound.

Key facts

Parent: alpha-MSH, 13 residues, 1,664.9 Da
Fragment: KPV, 3 residues, 342.43 Da
Discarded: Melanocortin receptor engagement
Retained: Reported anti-inflammatory activity
Additional change: Size permits intracellular access
Guaranteed?: No — fragments are different molecules

The clean case for a fragment

Fragment isolation is most defensible when a parent has two separable functions and only one is wanted. Alpha-MSH is close to that ideal: pigmentation runs through melanocortin receptor engagement by the core sequence, and anti-inflammatory activity localises to the C-terminus. Taking the C-terminus alone is a targeted separation rather than a hopeful truncation.

What changes beyond losing a function

Size, dramatically. Going from 1,665 Da to 342 Da is not a minor trim — it is a fivefold reduction that changes what the molecule can physically do. The parent cannot cross membranes; the fragment plausibly can. So the fragment is not simply the parent minus pigmentation, it is a molecule with different access to different compartments.

Research material referenced

KPV 10mg — third-party HPLC tested

View — £24.99

Why that cuts both ways

A fragment small enough to enter cells might act by a mechanism the parent never used, which would mean the anti-inflammatory activity of KPV and of alpha-MSH are not necessarily the same phenomenon. That possibility is rarely acknowledged, and it means parent-fragment read-across should be applied cautiously in both directions.

How this compares with the library's other fragments

TB-500 takes an internal motif from thymosin beta-4 and its most-cited findings actually used the parent. Modified GRF (1-29) takes GHRH's active fragment and retains full agonist activity. KPV sits between: the separation is well motivated, and the size change is large enough that the fragment is a genuinely different kind of molecule from its parent.

What the delivery work implies

The 2017 Molecular Therapy paper on targeted oral delivery indicates that reaching the intended tissue was the practical obstacle, not activity. A compound needing a delivery vehicle is one whose free form does not arrive where it is wanted — a real limitation and one the fragment inherited from being very small and rapidly cleared.

Extended research context

The KPV deep dive

Deep dive: two functions in one hormone, and the case for splitting them

Alpha-MSH is a thirteen-residue peptide cleaved from proopiomelanocortin, and it does two things that have almost nothing to do with each other. Its core sequence engages melanocortin receptors on melanocytes and drives melanin synthesis - the activity it is named for. Separately, it carries anti-inflammatory activity that Brzoska and colleagues localised to its C-terminal end, a paper titled 'terminal signal' precisely because the finding was that the signal sits at the terminus rather than in the receptor-binding core. That is an unusually clean functional separation, and it produced two research compounds pulling in opposite directions from one parent. KPV takes the C-terminal three residues and discards the pigmentation activity. Melanotan II does the reverse - a cyclic analogue built around the receptor-binding portion to maximise exactly what KPV was designed to leave behind. Same hormone, opposite halves.

Deep dive: what happens when you shrink a molecule fivefold

Going from alpha-MSH at 1,664.9 Da to KPV at 342.43 Da is not a trim, it is a change of category. A 1,665 Da peptide is firmly a cell-surface ligand - far too large to cross a membrane passively, so whatever it does must begin at a receptor. A 342 Da tripeptide is small enough that intracellular access becomes plausible, which is why KPV's reported mechanism is described in terms of NF-kappaB signalling rather than melanocortin receptor engagement. The consequence is rarely stated: if the fragment acts inside the cell and the parent acts at its surface, then the anti-inflammatory activity of the two is not necessarily the same phenomenon, and read-across between them should run cautiously in both directions. Fragment logic assumes the fragment is the parent minus something. Here it may be the parent minus something plus a different route of access.

Deep dive: the delivery paper is the most informative thing in the literature

Xiao and colleagues published in Molecular Therapy in 2017 on delivering KPV orally using hyaluronic acid-functionalised nanoparticles targeted to inflamed intestinal tissue. Read as a result it is a delivery success. Read as a statement about the compound it is more interesting: nobody builds a targeted nanoparticle carrier for a molecule that already reaches its target. The existence of that work says the free tripeptide's arrival at inflamed tissue was the limiting problem - which follows directly from being 342 Da, highly soluble and rapidly cleared. It is the same signal that CJC-1295's DAC modification carries for growth hormone secretagogues, or that lipidation carries across the whole incretin class: when the engineering effort goes into getting a compound to stay and arrive rather than into making it more active, the pharmacokinetics were the bottleneck.

Research applications

▸Melanocortin fragment structure-activity research
▸NF-kappaB pathway and cytokine production studies in culture
▸Murine models of induced intestinal inflammation
▸Targeted peptide delivery and carrier system development
▸Comparative work on parent hormones and isolated fragments
▸Analytical method development for very short peptides

Handling checklist

✓Verify identity against Lys-Pro-Val, CID 125672, at 342.43 Da
✓Do not search PubChem for 'KPV' - it returns an unrelated organic acid
✓Store lyophilised, cold, dry and dark
✓Use low-binding consumables; a small cationic peptide adsorbs to surfaces
✓Reconstitute gently down the vial wall and swirl, never shake
✓Aliquot into single-use volumes to avoid freeze-thaw cycling
✓Expect no disulfide or oxidation satellites - no cysteine, no methionine

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Searching PubChem for 'KPV' to verify a certificate

Fix: That returns CID 13294447, 2-oxo-5-phenylpentanoic acid at 192.21 Da, an unrelated compound. Search Lys-Pro-Val for CID 125672.

✗ Treating KPV and alpha-MSH findings as interchangeable

Fix: They differ fivefold in mass and the fragment may act intracellularly where the parent cannot. Read across cautiously in both directions.

✗ Assuming a colitis model result speaks to inflammatory bowel disease

Fix: Induced colitis in a mouse is acute and chemical; human IBD is chronic, heterogeneous and immunologically complex.

✗ Expecting to quantify KPV by absorbance at 280 nm

Fix: There is no aromatic residue in the sequence, so there is no usable absorbance there.

✗ Attributing unexplained low recovery to degradation

Fix: KPV is chemically robust - no cysteine, methionine or asparagine. Adsorption to glass and plastic is the more likely cause.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why not just use alpha-MSH?: It drives pigmentation through melanocortin receptors, which is a confound for anti-inflammatory research. The fragment separates the two activities.
Does KPV work the same way as its parent?: Not necessarily. At a fifth of the mass it may access compartments alpha-MSH cannot, so the mechanisms may differ.
What limits KPV in practice?: Delivery. The published targeted-delivery work indicates the free tripeptide's arrival at intended tissue was the obstacle.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum